Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Commission to double pharmaceutical research spending but more needs to be done

25.06.2002


"I would like Europe to become a centre of excellence and a focus for pharmaceutical research once again", stated EU Research Commissioner Philippe Busquin today at the annual assembly of the European pharmaceutical industry (EFPIA) in Bruges. "We need to nurture our research-based industries by reinforcing science and technology in Europe. Europe needs to invest more and in a better, more consistent way: it has to cut red tape and be bold." From 1999 to 2002 the Commission invested around € 1 billion in health-related research. In the next four years, within the new EU research framework programme, at least € 2 billion will be spent in this area, with a particular priority on genomics and biotechnology for health. But this is not enough. In recent years, the competitiveness of EU pharmaceutical industry has decreased. The fact is that the US, with a bigger market for drugs, in particular those based on advances in bio-medicines, has overtaken the EU in total research investment. "The EU has been late in grasping the potential of biotechnology for the development of new drugs," says Commissioner Busquin. "But Europe is catching up: new biotech companies are created every year in the EU. Professional technology transfer and investments in collaborative biotechnology research programmes are on the rise. Our latest Research Programme will foster the competitiveness of the European pharmaceutical industry. But EU funding will only have sufficient leverage if pharmaceutical companies and Member States join us in networking research efforts at EU level."



Commissioner Busquin also refers to the conclusions of the recent Commission Communication on "Biotechnology and Life Sciences": "The Commission and Member States need to work more closely together to develop coherent policies for making the most of biotechnology and life sciences. This will benefit public health and the competitiveness of the European pharmaceutical industry."

"Of course we cannot expect the pharmaceutical industry to invest as much in research as in the US, if the value of the EU market remains at only about half of that of the US, particularly if it does not seem to encourage the introduction of innovative drugs" adds Commissioner Busquin. "Despite this, the EU is only slightly behind the US in terms of biotech patenting activity and in terms of scientific publications we are as good as the US. Indeed, our goal is to attract more investment into EU biotech and pharmaceutical research, whether from EU or US industry, and to make the EU research and innovation system more effective in terms of innovative output".


Action at EU level

The European Union, through its Framework Programmes for Research and Technological Development, has given substantial financial support to research relevant to the pharmaceutical industry. In the 5th Framework programme (1998-2002) the Commission invested close to € 1 billion, mainly in biotechnology, vaccine development, disease understanding, and also in bioinformatics and new drug delivery methods using nanotechnologies. In the new framework programme (2002-2006) with its major focus on "Life Sciences: Genomics and Biotechnology for Health", the Commission is likely to double this amount. The use of new instruments such as networks of excellence and integrated projects will bring together expertise at EU level, as recommended in the G10 High Level Group on Innovation and the Provision of Medicines report(1). This is also in line with the European Research Area strategy and Commissioner Busquin’s proposal to increase research spending to 3% of GDP by 2010, as adopted by the March 2002 European Council in Barcelona.

The situation of pharmaceutical industry in Europe

For most of the past decade, Europe has led in pharmaceutical innovation. In 1997, however, the US overtook Europe for the first time, both in terms of research and development (R&D) investment and output (new drug candidates). In 1990, EU pharmaceutical industry spent 73% of its R&D budget in Europe, but this figure dropped to only 59% in 1999 and the US is now spending €24 billion compared to €17 billion in the EU. Spurred by more open market regulations, the world market share of US pharmaceutical products jumped in the same period from 31% to 43%, while in price-controlled EU the figure dropped from 32% to 22%.

The competitiveness of US industry has also benefited from a more vigorous exploration of new technological opportunities. Increased professional technology transfer from the public research sector and the establishment of a vibrant biotechnology industry is providing innovative products based on new biotechnological developments to the pharmaceutical industry.

On the rise again

The EU is nevertheless catching up. A large number of Member States, including France and Germany, have recently put in place new regulations for the exploitation of publicly funded research, or implemented tax laws favouring research investments similar to the UK. Some Member States are also actively supporting the establishment of professional technology transfer structures. The number of biotech companies in Europe increased dramatically in recent years. In 2001 there were more companies in the EU (1879) than in the US (1457). Although turnover and employment figures in the US industry are double those of the EU, the EU growth rates have consistently outperformed those of the US in recent years, thus starting to close the gap. Interestingly enough, the EU industry was able to reduce its net loss by 16% to US$1.5 billion in 2001, while losses in the US industry, mostly public companies, increased 15% to US$6.9billion.

The availability of private risk capital for biotechnology in the EU, which increased since 1995 by a factor of 8 to reach around €1 billion in the year 2000, has been one of the major success factors for the growth of the biotech industry in Europe. In 2001, despite a worldwide economic downturn, biotech investments in Europe only dropped by 17% from the previous year, compared to a 31% drop in overall high tech investments.

Commission research efforts aim at consolidating the lead of EU companies where they outperform US competitors, and in helping them fill the gap in sectors where they are trailing the US. Pooling together high-level, cutting-edge research know-how and infrastructures will foster a true European Research Area in the pharmaceutical sector.

fabio Fabbi | Europäische Kommission
Further information:
http://europa.eu.int/comm/research/quality-of-life.html

More articles from Life Sciences:

nachricht New mechanisms uncovered explaining frost tolerance in plants
26.09.2016 | Technische Universität München

nachricht Chains of nanogold – forged with atomic precision
23.09.2016 | Suomen Akatemia (Academy of Finland)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

Im Focus: Complex hardmetal tools out of the 3D printer

For the first time, Fraunhofer IKTS shows additively manufactured hardmetal tools at WorldPM 2016 in Hamburg. Mechanical, chemical as well as a high heat resistance and extreme hardness are required from tools that are used in mechanical and automotive engineering or in plastics and building materials industry. Researchers at the Fraunhofer Institute for Ceramic Technologies and Systems IKTS in Dresden managed the production of complex hardmetal tools via 3D printing in a quality that are in no way inferior to conventionally produced high-performance tools.

Fraunhofer IKTS counts decades of proven expertise in the development of hardmetals. To date, reliable cutting, drilling, pressing and stamping tools made of...

Im Focus: Launch of New Industry Working Group for Process Control in Laser Material Processing

At AKL’16, the International Laser Technology Congress held in May this year, interest in the topic of process control was greater than expected. Appropriately, the event was also used to launch the Industry Working Group for Process Control in Laser Material Processing. The group provides a forum for representatives from industry and research to initiate pre-competitive projects and discuss issues such as standards, potential cost savings and feasibility.

In the age of industry 4.0, laser technology is firmly established within manufacturing. A wide variety of laser techniques – from USP ablation and additive...

Im Focus: New laser joining technologies at ‘K 2016’ trade fair

Every three years, the plastics industry gathers at K, the international trade fair for plastics and rubber in Düsseldorf. The Fraunhofer Institute for Laser Technology ILT will also be attending again and presenting many innovative technologies, such as for joining plastics and metals using ultrashort pulse lasers. From October 19 to 26, you can find the Fraunhofer ILT at the joint Fraunhofer booth SC01 in Hall 7.

K is the world’s largest trade fair for the plastics and rubber industry. As in previous years, the organizers are expecting 3,000 exhibitors and more than...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Experts from industry and academia discuss the future mobile telecommunications standard 5G

23.09.2016 | Event News

ICPE in Graz for the seventh time

20.09.2016 | Event News

Using mathematical models to understand our brain

16.09.2016 | Event News

 
Latest News

Stronger turbine blades with molybdenum silicides

26.09.2016 | Materials Sciences

Scientists Find Twisting 3-D Raceway for Electrons in Nanoscale Crystal Slices

26.09.2016 | Materials Sciences

Lowering the Heat Makes New Materials Possible While Saving Energy

26.09.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>